Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts

Journal of Pathology

Volumn 227, Issue 1, 2012, Pages 118-129

  Fenouille, Nina ^a,b   Grosso, Sebastien ^b,c   Su, Yunchao ^d   Didier, Mary ^a,b   Pontier Bres, Rodolphe ^a,b   Imbert, Véronique ^a,b   Czerucka, Dorota ^a,b   Caroli Bosc, François Xavier ^e   Peyron, Jean François ^a,b,f   Lagadec, Patricia ^a,b  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Advanced colorectal cancer; Annexin A2; Biomarkers; Calpain 2; CPT 11 SN 38; Drug resistance; NF B; S100A10

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CALPAIN 2; ETOPOSIDE; FLUOROURACIL; I KAPPA B; I KAPPA B ALPHA; IRINOTECAN; LIPOCORTIN 2; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HT29; COLORECTAL CANCER; CYTOTOXICITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; ANNEXIN A2; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALPAIN; CAMPTOTHECIN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; I-KAPPA B PROTEINS; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PYRIMIDINES; S100 PROTEINS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859631303     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3034     Document Type: Article

References (42)

1. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518. (Pubitemid 32202559)
2. Del Rio M, Molina F, Bascoul-Mollevi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007; 25: 773-780. (Pubitemid 350002876)
3. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin. Ann NY Acad Sci 2000; 922: 1-10. (Pubitemid 32050237)
4. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13: 1841-1851. (Pubitemid 36040772)
5. Lagadec P, Griessinger E, Nawrot MP, et al. Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 2008; 98: 335-344. (Pubitemid 351161231)
6. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105: 804-811. (Pubitemid 40070768)
7. Camp ER, Li J, Minnich DJ, et al. Inducible nuclear factor-κB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199: 249-258. (Pubitemid 38962737)
8. Weaver KD, Yeyeodu S, Cusack JC, Jr, et al. Potentiation of chemotherapeutic agents following antagonism of nuclear factor κB in human gliomas. J Neurooncol 2003; 61: 187-196. (Pubitemid 36342295)
9. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 1999; 18: 6867-6874.
10. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853-6866.
11. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ 2006; 13: 773-784.
12. Brzoska K, Szumiel I. Signalling loops and linear pathways: NF-κB activation in response to genotoxic stress. Mutagenesis 2009; 24: 1-8.
13. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1489.
14. Le Brigand K, Russell R, Moreilhon C, et al. An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. Nucleic Acids Res 2006; 34: e87.
15. Moreilhon C, Gras D, Hologne C, et al. Live Staphylococcus aureus and bacterial soluble factors induce different transcriptional responses in human airway cells. Physiol Genomics 2005; 20: 244-255. (Pubitemid 40388524)
16. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004; 20: 3705-3706. (Pubitemid 40136823)
17. Le Brigand K, Barbry P. Mediante: a web-based microarray data manager. Bioinformatics 2007; 23: 1304-1306. (Pubitemid 47050552)
18. Li Q, Laumonnier Y, Syrovets T, et al. Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2007; 27: 1383-1389. (Pubitemid 46809429)
19. Han Y, Weinman S, Boldogh I, et al. Tumor necrosis factor- α-inducible IκBα proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-κB activation. J Biol Chem 1999; 274: 787-794.
20. Zobiack N, Gerke V, Rescher U. Complex formation and submembranous localization of annexin 2 and S100A10 in live HepG2 cells. FEBS Lett 2001; 500: 137-140. (Pubitemid 32607548)
21. Schaecher K, Goust JM, Banik NL. The effects of calpain inhibition on IκBα degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 2004; 29: 1443-1451. (Pubitemid 39011333)
22. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67: 1270-1281.
23. Gu Z, Lee RY, Skaar TC, et al. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res 2002; 62: 3428-3437. (Pubitemid 34651389)
24. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007; 25: 3930-3935. (Pubitemid 47477270)
25. Allen WL, Coyle VM, Jithesh PV, et al. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res 2008; 14: 6647-6655.
26. Vie N, Copois V, Bascoul-Mollevi C, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008; 7: 14.
27. Choi DH, Ha JS, Lee WH, et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 2007; 581: 1649-1656. (Pubitemid 46528931)
28. Owatari S, Akune S, Komatsu M, et al. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 2007; 67: 4860-4868. (Pubitemid 46910194)
29. Abal M, Bras-Goncalves R, Judde JG, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004; 23: 1737-1744. (Pubitemid 38445165)
30. Raynal C, Pascussi JM, Leguelinel G, et al. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 2010; 9: 46-59.
31. Coss A, Tosetto M, Fox EJ, et al. Increased topoisomerase IIαexpression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett 2009; 276: 228-238.
32. Chikazawa N, Tanaka H, Tasaka T, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30: 2041-2048.
33. Tai IT, Dai M, Owen DA, et al. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005; 115: 1492-1502. (Pubitemid 40814658)
34. Wang F, Liu R, Lee SW, et al. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007; 26: 2006-2016. (Pubitemid 46514736)
35. Rescher U, Gerke V. S100A10/p11: family, friends and functions. Pflugers Arch 2008; 455: 575-582. (Pubitemid 350160469)
36. Sarkar S, Swiercz R, Kantara C, et al. Annexin A2 mediates upregulation of NF-κB, β-catenin, CD44, and DCAMKL+1 in response to progastrin in mice and HEK-293 cells. Gastroenterology 2011; 140: 583-595.
37. Lakshmikuttyamma A, Selvakumar P, Kanthan R, et al. Overexpression of m-calpain in human colorectal adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2004; 13: 1604-1609. (Pubitemid 39331881)
38. Jang JS, Lee SJ, Choi YH, et al. Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease. Oncogene 1999; 18: 1789-1796. (Pubitemid 29145846)
39. Zhu H, Zhang L, Huang X, et al. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004; 9: 666-673. (Pubitemid 38660419)
40. Zhu H, Zhang L, Dong F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24: 4993-4999. (Pubitemid 41129103)
41. Li C, Chen S, Yue P, et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradation. J Biol Chem 2010; 285: 16096-16104.
42. Storr SJ, Carragher NO, Frame MC, et al. The calpain system and cancer. Nat Rev Cancer 2011; 11: 364-374.